Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIGA: Glucocorticoids Plus Rituximab vs Glucocorticoids Plus Placebo in IgA Vasculitis
2024-516052-17-01Phase 3Authorised
- Sponsor
- Hôpital Foch
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Henoch-Schönlein Purpura (HSP) comparing Rituximab + glucocorticoids with Placebo + glucocorticoids (2 arms). Primary endpoint: Primary: Remission without prednisone at days 180 and 360. Planned start Nov 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
Henoch-Schönlein Purpura (HSP)
Beyond the preview
Go deeper on 2024-516052-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516052-17-01.